NICE opens door to Roche, AZ cancer drugs

The U.K.'s cost-effectiveness watchdog has given the final nod to a trio of cancer drugs--Roche's Xeloda and MabThera, and AstraZeneca's Iressa--which means the NHS must provide funding and resources for them in the next three months. Report